Catalyst MedTech Brings Innovation to U.S. Neurology Imaging
Catalyst MedTech, a prominent name in nuclear medicine and molecular imaging, has recently announced an exciting development in its portfolio—the exclusive U.S. distribution rights for the
CareMiBrain™ PET system, a cutting-edge technology developed by OncoVision. This strategic partnership is aimed at significantly enhancing advanced neurologic imaging capabilities throughout the country, answering a growing need for effective diagnostic solutions in the realm of neurology.
The Game-Changing CareMiBrain™ Technology
The
CareMiBrain™ system is engineered specifically for advanced neurologic imaging and research. With ultra-high resolution and high sensitivity, it ensures patient comfort while providing exceptional imaging quality in a compact setup that can integrate easily into various clinical environments. It is designed for imaging departments, outpatient centers, or private practices, thereby expanding accessibility for healthcare providers and patients alike.
Catalyst MedTech will showcase this innovative system for the first time at the
SNMMI 2025 Annual Meeting in New Orleans, at Booth #701. This highly anticipated event will feature the unveiling of CareMiBrain™ in conjunction with
NeuroQ4™, an advanced brain analysis software committed to optimizing neurologic PET imaging for conditions such as Epilepsy, Oncology, and Amyloid Analysis. This pairing is viewed by Catalyst MedTech as pivotal in providing American physicians with an integrative solution that elevates diagnostic capabilities.
A Strategic Move
Martin Shirley, President and CEO of Catalyst MedTech, emphasizes the significance of this distribution agreement. He states, “This is more than a distribution agreement. It represents a definitive milestone in our commitment to enhancing patient care through advanced imaging solutions. Our goal is to propel healthcare forward, and with the CareMiBrain™ paired with NeuroQ4™, we are perfectly positioned to do just that.”
Key Features of the CareMiBrain™ PET System
Among the notable advantages of the CareMiBrain™ system are:
- - Spatial Resolution: Achieves a remarkable spatial resolution of less than 1.6 mm, facilitating advanced diagnostics.
- - Clinical Performance: Proven efficacy with over 600 patients, delivering reliable imaging results, particularly in amyloid and tau studies.
- - Patient-Centric Design: Ergonomically designed for patient comfort with reclining capabilities and rapid acquisition times.
- - Flexibility and Integration: Operates on versatile power sources (115–240V), producing minimal heat and requiring a modest room size of approximately 8'x13'.
- - Comprehensive Software Support: Includes fully integrated acquisition, quantification, and reconstruction software, with optional integration with NeuroQ4™ for in-depth brain analysis.
The Role of NeuroQ4™
The
NeuroQ4™, a flagship brain imaging analysis software available from SynterMed, enhances the capabilities of CareMiBrain™ by offering:
- - Enhanced FDG-PET imaging specifically designed for oncology and epilepsy.
- - Comprehensive Amyloid Analysis, crucial for monitoring and diagnosing neurodegenerative diseases.
- - Tools for Serial Comparison to track disease progression effectively.
- - A detailed view of dementia, which can significantly influence therapy decisions.
Catalyst MedTech's Mission and Vision
Catalyst MedTech is committed to providing tailored solutions that address diagnostic challenges faced by healthcare providers. By delivering a system thoughtfully designed for both clinical and operational impact, they are not only expanding patient access but also driving innovation within the field. With an
ISO-certified service infrastructure and an OEM approach, Catalyst aims to empower healthcare professionals and partners to